{"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}],"groups":[{"description":"The usual adult dosage for oral administration was 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle was repeated for 6 cycles. The dose might be reduced appropriately according to the patient's condition. Participants received interventions as part of routine medical care.","id":"BG000","title":"Ixazomib 4 mg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.85","value":"70.6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"391"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"351"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"742"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}],"title":"Japan"}],"description":"All participants were enrolled in Japan.","paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.902","value":"4.49"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"739"}],"units":"Participants"}]}],"description":"Mean duration between the first diagnosis of relapsed/refractory multiple myeloma and the start of the study was reported.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Duration of Diagnosis of Relapsed/Refractory Multiple Myeloma","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"742"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Participants with Relapsed/Refractory Multiple Myeloma","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"140"}],"title":"Stage I"},{"measurements":[{"groupId":"BG000","value":"260"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"290"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"50"}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"BG000","value":"740"}],"units":"Participants"}]}],"description":"International Staging System is a staging system for cancer progression. Stages are classified by Stage I to Stage III. Stage I: Serum beta2-microglobulin \\<3.5 mg/L and albumin ≥3.5 g/dL; Stage II: Neither Stage I or III, meaning that either: beta2-microglobulin level ≥3.5 and \\<5.5 mg/L (with any albumin level), OR albumin \\<3.5 g/dL with beta2-microglobulin \\<3.5 mg/L; Stage III: Serum beta2-microglobulin ≥5.5 mg/L. Normal serum beta2-microglobulin: \\<3.0 mg/L; normal albumin: 3.5-5.0 g/dL.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"International Staging System","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"240"}],"title":"Scale = 0"},{"measurements":[{"groupId":"BG000","value":"294"}],"title":"Scale = 1"},{"measurements":[{"groupId":"BG000","value":"112"}],"title":"Scale = 2"},{"measurements":[{"groupId":"BG000","value":"81"}],"title":"Scale = 3"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Scale = 4"}],"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}]}],"description":"Eastern Cooperative Oncology Group performance status assess participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than \\[\\>\\] 50 percent \\[%\\] of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self-care, confined to bed/chair \\>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"436"}],"title":"Outpatient"},{"measurements":[{"groupId":"BG000","value":"306"}],"title":"Inpatient"}],"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Healthcare Category","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"696"}],"title":"Had No Hepatic Impairment"},{"measurements":[{"groupId":"BG000","value":"46"}],"title":"Had Hepatic Impairment"}],"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Hepatic Impairment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"448"}],"title":"Had No Renal Impairment"},{"measurements":[{"groupId":"BG000","value":"294"}],"title":"Had Renal Impairment"}],"denoms":[{"counts":[{"groupId":"BG000","value":"742"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Renal Impairment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"307"}],"title":"Had No Medical Complications"},{"measurements":[{"groupId":"BG000","value":"434"}],"title":"Had Medical Complications"}],"denoms":[{"counts":[{"groupId":"BG000","value":"741"}],"units":"Participants"}]}],"description":"Complications defined as a disease or a health condition for each participant at the start of study. Complications were classified as congenital anomalies, endocrine disorders, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, gastrointestinal (GI) disorders, renal disease and other complications. Other complications included all complications except for those mentioned above.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Medical Complications","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"475"}],"title":"Had No Medical History"},{"measurements":[{"groupId":"BG000","value":"259"}],"title":"Had Medical History"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"741"}],"units":"Participants"}]}],"description":"Medical history defined as a disease or a health condition for each participant before start of the study. Medical history was classified as congenital anomalies, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, GI disorders, hepatic and biliary disorders, renal disease and other medical history. Other medical history included all medical history except for those mentioned above. Unknown: Data could not be collected.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Medical History","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.01","value":"156.2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"715"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Height","unitOfMeasure":"Centimeters (cm)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.764","value":"54.10"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"709"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Weight","unitOfMeasure":"Kilograms (kg)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.204","value":"1.53"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"705"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The number analyzed is the number of participants with data available for analysis.","title":"Body Surface Area","unitOfMeasure":"Square Meter"}],"populationDescription":"Safety Analysis Set, The safety analysis set was defined as all participants who completed the survey."}